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ABSTRACT
Spinal muscular atrophy (SMA) is an inherited neurodegenerative
condition caused by a reduction in the amount of functional survival
motor neuron (SMN) protein. SMN has been implicated in transport of
mRNA in neural cells for local translation. We previously identified
microtubule-dependent mobile vesicles rich in SMN and SNRPB, a
member of the Sm family of small nuclear ribonucleoprotein (snRNP)-
associated proteins, in neural cells. By comparing the interactomes of
SNRPB and SNRPN, a neural-specific Sm protein, we now show that
the essential neural protein neurochondrin (NCDN) interacts with Sm
proteins and SMN in the context of mobile vesicles in neurites. NCDN
has roles in protein localisation in neural cells and in maintenance of
cell polarity. NCDN is required for the correct localisation of SMN,
suggesting they may both be required for formation and transport of
trafficking vesicles. NCDN may have potential as a therapeutic target
for SMA together with, or in place of the targeting of SMN expression.
This article has an associated First Person interview with the first
author of the paper.
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INTRODUCTION
The inherited neurodegenerative disease spinal muscular atrophy
(SMA) is caused by a reduction in the amount of functional survival
motor neuron (SMN) protein (Lefebvre et al., 1995). SMA is the
leading genetic cause of infant mortality, affecting 1:6000 live
births (Monani, 2005). The recently developed therapy, treatment
with Spinraza/Nusinersen (Biogen), has been shown to increase the
level of SMN and improve the symptoms of SMA patients (Corey,
2017; Finkel et al., 2016; Passini et al., 2011). Most SMA patients
harbour mutations in the SMN1 gene, which produces the majority
of total SMN protein in cells. In humans, expression from a variable
number of copies of an additional gene, SMN2, can produce some
full-length SMN protein (Lefebvre et al., 1995, 1997). The SMN2
gene, unlike SMN1, contains a point mutation in an exon splicing
enhancer (Lorson and Androphy, 2000; Lorson et al., 1999) resulting
in truncation ofmost of the SMN protein produced by SMN2 through
skipping of exon 7. The truncated protein produced by SMN2 is less
stable than full-length SMN and cannot compensate fully for the loss
of SMN1 (Le et al., 2005; Lorson and Androphy, 2000; Lorson et al.,
1999). However, owing to the small amounts of full-length SMN
expressed from the SMN2 gene, the number of gene copies can
influence the severity of SMA, with evidence that five copies of
SMN2 may be enough to compensate for loss of SMN1 (Campbell
et al., 1997; Prior et al., 2004). It is not currently clear how a
deficiency of functional SMN leads to the specific symptoms of
SMA. In particular, the differing sensitivity of cell types to lowered
SMN levels, with motor neurons most severely affected, is difficult to
explain as SMN is an essential protein and complete deletion is lethal
at the cellular level (Hsieh-Li et al., 2000; Schrank et al., 1997).
SMN localises to nuclear Cajal bodies (CBs) and gemini of Cajal
bodies (gems) (Liu and Dreyfuss, 1996) as well as in the cytoplasm,
and is implicated in a growing number of cellular roles in both
locations (Hosseinibarkooie et al., 2017; Li et al., 2014; Monani,
2005; Singh et al., 2017; Sleeman, 2013; Tisdale and Pellizzoni,
2015). The first role to be elucidated was a role in the early,
cytoplasmic, stages of assembly and maturation of splicing small
nuclear ribonucleoproteins (snRNPs). Splicing snRNPs are
ribonucleoprotein complexes that are essential for pre-mRNA
splicing, and comprise a small nuclear RNA (snRNA) core and
numerous proteins, including a heptameric ring containing one copy
each of members of the Sm protein family. SMN is part of a
cytoplasmic complex, also containing the gemin proteins that is
required for the addition of the Sm proteins as a ring around the
snRNA core (Li et al., 2014; Liu et al., 1997; Stark et al., 2001;
Tisdale and Pellizzoni, 2015). The maturation of snRNPs has been
shown to be impaired by a deletion in SMN (Gabanella et al., 2007;
Shpargel and Matera, 2005; Wan et al., 2005; Winkler et al., 2005;
Zhang et al., 2008), while alterations to pre-mRNA splicing events,
proposed to be a downstream consequence of this impairment, have
been observed in several models of SMA (Custer et al., 2013; Huo
et al., 2014; Zhang et al., 2008). One of the proposed mechanisms
for the cell-type specificity of SMA is that these alterations of
pre-mRNA splicing events affect mRNA transcripts that are
essential for motor neurons, perhaps preferentially affecting
transcripts spliced by the minor spliceosome (Boulisfane et al.,
2011; Custer et al., 2016; Doktor et al., 2017; Gabanella et al., 2007;
Zhang et al., 2008). Despite promising results in Drosophila
models, however, specific transcripts affecting motor neurons are
yet to be conclusively identified (Lotti et al., 2012).
Another well-established cellular role of SMN is in the trafficking
of mature mRNAwithin the cytoplasm, particularly in the axons and
neurites of neural cell types (Akten et al., 2011; Custer et al., 2013;
Fallini et al., 2016, 2014, 2011; Li et al., 2015; Lotti et al., 2012;
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Zhang et al., 2006, 2003). This is thought to be linked to local
translation of mRNA into proteins, an important process for neural
cells, in particular motor neurons, owing to the length of their axons
(Doyle and Kiebler, 2011; Holt and Schuman, 2013; Huber et al.,
2000; Kang and Schuman, 1996), making this trafficking role for
SMN of particular interest for understanding the cellular pathology
of SMA. SMN colocalises with the mRNA-binding proteins HuD
(also known as ELAVL4), IMP1 (also known as IGF2BP1) and
heterogeneous nuclear RNP (hnRNP) R and is involved in the
localisation of mRNAs to axons (Akten et al., 2011; Fallini et al.,
2014, 2011; Rossoll et al., 2003). The cellular structures involved in
SMN-dependent mRNA trafficking are currently unclear, being
described as granular (Akten et al., 2011; Fallini et al., 2014; Peter
et al., 2011; Todd et al., 2010b; Zhang et al., 2006, 2003) or
vesicular in nature (Custer et al., 2013; Prescott et al., 2014).
SMN has also been implicated in many other processes. Some of
these involve a role in RNP assembly, similar to the canonical role in
splicing snRNP production, including assembly of both the signal
recognition particle and the U7 snRNP required for 3′ processing of
histone mRNA (Azzouz et al., 2005; Piazzon et al., 2013; Tisdale
et al., 2013). Other roles are more diverse, and include the regulation
of cytoskeletal dynamics and endocytosis (Bowerman et al., 2007;
Dimitriadi et al., 2016; Giesemann et al., 1999; Hao le et al., 2012;
Heesen et al., 2016; Hosseinibarkooie et al., 2016; Nölle et al.,
2011; Oprea et al., 2008; Riessland et al., 2017), enhancement of
DNA repair (Takaku et al., 2011); transcriptional regulation
(Pellizzoni et al., 2001; Zhao et al., 2016; Zou et al., 2004), stress
granule formation (Hua and Zhou, 2004; Zou et al., 2011) and
ubiquitin homeostasis (Wishart et al., 2014). It is currently unclear
whether or how disruption of the many proposed roles for SMN
contributes to SMA pathogenesis.
Structures containing both the SMN and SNRPB (also known as
SmB) proteins, alongside coatomer γ are trafficked on microtubules
(Prescott et al., 2014). Evidence suggesting that SMN- and SNRPB-
rich structures are vesicular in nature includes their staining with
lipophilic dyes in living neural cells, their COPI vesicular appearance
as seen with correlative fluorescence and electron microscopy
(Prescott et al., 2014), and the interaction of SMN and the Sm
proteins with coatomer proteins, which are associated with
membrane-bound COPI vesicles (Custer et al., 2013; Peter et al.,
2011; Prescott et al., 2014). We have previously identified an
interaction between SNRPB and dynein cytoplasmic 1 heavy chain 1
(DYNC1H1), a motor protein required for microtubule transport
(Prescott et al., 2014), mutation in which can cause a rare, lower-
extremity dominant SMA (Chen et al., 2017; Ding et al., 2016; Harms
et al., 2010, 2012; Niu et al., 2015; Peeters et al., 2015; Punetha et al.,
2015; Scoto et al., 2015; Strickland et al., 2015; Tsurusaki et al.,
2012). SMN has also been shown to associate with the membranous
Golgi complex (Ting et al., 2012), while mutations in the Golgi-
related protein bicaudal D homolog 2 (BICD2) also cause a form of
lower-extremity dominant SMA (Martinez-Carrera and Wirth, 2015;
Neveling et al., 2013; Oates et al., 2013; Peeters et al., 2013; Rossor
et al., 2015; Synofzik et al., 2014).
The Sm protein family is implicated in both of the major
functions of SMN. The core of splicing snRNPs comprises a
heptameric ring of proteins around the snRNA, containing SNRPB
and/or its alternatively spliced variant SNRPB′, SNRPD1,
SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG (Urlaub et al.,
2001). SMN is a vital part of the complex required for the assembly
of this Sm protein ring (Battle et al., 2006; Fischer et al., 2011, 1997;
Liu and Dreyfuss, 1996; Meister et al., 2001; Meister and Fischer,
2002; Pellizzoni et al., 2002). Other members of the Sm protein
family have also been identified, beyond the core proteins usually
found in splicing snRNPs. Of particular interest in the context of
SMA pathology is SNRPN (this protein is also known as SmN,
denoted with a lowercase ‘m’), which is expressed in neural tissues
(Schmauss et al., 1992) and can replace SNRPB in the heptameric
Sm protein ring (Huntriss et al., 1993). The human SNRPN protein
differs from SNRPB′ by 17 amino acids (UniProt identifiers P63162
and P14678, respectively), and little is known about its behaviour
other than its incorporation into snRNPs, although the SNRPN gene
locus is within the paternally imprinted region of the genome critical
in Prader–Willi syndrome (Özçelik et al., 1992). There is growing
appreciation that some Sm proteins may ‘moonlight’ in functions
beyond their presence in splicing snRNPs. In addition to the role of
SNRPB in cytoplasmic trafficking vesicles in human cells, in
Drosophila the homologues of SNRPB and SNRPD3 are implicated
inmRNA localisation (Gonsalvez et al., 2010) and SNRPD1 has a role
in micro (mi)RNA biogenesis (Xiong et al., 2015). With this in mind,
we applied a proteomic approach in the neural cell line SH-SY5Y to
search for interactions that could indicate neural-specific roles for the
SNRPN protein that are of relevance for the pathology of SMA.
This proteomic approach led to the identification of neurochondrin
(NCDN) as a novel interactor of both SNRPN and SMN.NCDN is an
essential protein that is predominantly expressed in neural tissue, and
is involved in neural outgrowth, synaptic plasticity and moderation of
signal transduction (Dateki et al., 2005; Francke et al., 2006; Matosin
et al., 2015; Pan et al., 2016; Shinozaki et al., 1999, 1997;Wang et al.,
2013, 2009; Ward et al., 2009). Further investigation of the
relationship between NCDN and SMN suggests that NCDN
interacts with SMN in the context of mobile cytoplasmic vesicles
containing SNRPB and SNRPN and is strongly expressed in motor
neurons. This suggests that NCDN warrants further investigation in
the context of SMA pathology and that it might prove useful as a
target for future therapy development.
RESULTS
SNRPN exhibits similar behaviour to SNRPB, localising to
cytoplasmic vesicles containing SMN
In order to determine the interactome of the neural-specific Sm
protein SNRPN, we first generated constructs to express fluorescent
protein-tagged SNRPN by amplifying the SNRPN sequence from
total RNA obtained from SH-SY5Y cells and cloning it into the
pEYFP-C1 and pmCherry-C1 vectors. All of the Sm fusion proteins
studied so far show a steady-state localisation to nuclear CBs and
speckles. The Sm proteins SNRPB, SNRPD1 and SNRPE have also
previously been shown to exhibit a characteristic pathway within the
cell on their initial expression, indicative of the snRNP maturation
pathway (Sleeman and Lamond, 1999), although differences were
seen between the Sm proteins. To confirm that YFP–SNRPN
localised correctly at steady state to CBs and speckles, and to
determine where SNRPN localised during maturation and
incorporation into snRNPs, the plasmid was transiently expressed
in SH-SY5Y neuroblastoma cells, with cells fixed and
immunostained at 24 h intervals. At 48 and 72 h after
transfection, YFP–SNRPN predominantly localised to speckles
and CBs (as detected with anti-coilin antibody) identically to
endogenous Sm proteins (detected with Y12 antibody), whereas at
24 h, YFP–SNRPN localised predominantly diffusely within the
cytoplasm, with some accumulation in CBs (Fig. 1A,B). This
sequential localisation is indistinguishable from that previously
observed with YFP–SNRPB in HeLa andMCF-7 cells, though CBs
were not prominent in the majority of SH-SY5Y cells transiently
expressing YFP–SNRPN. Equivalent results were also obtained in
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SH-SY5Y cells transiently expressing mCherry–SNRPN (Fig. S1).
Both YFP–SNRPN and mCherry–SNRPN are efficiently
incorporated into splicing snRNPs, as evidenced by their enrichment
fromwhole-cell lysates when using antibodies against the characteristic
hypermethylated Cap structure (2,2,7-trimethylaguanosine) found on
snRNAs (Fig. 1C).
To determine whether the similarities between SNRPN and
SNRPB extend to their localisation in detergent-sensitive vesicles in
the cytoplasm (Prescott et al., 2014), SH-SY5Y cells constitutively
expressing mCherry–SNRPN were used for live-cell time-lapse
microscopy. Mobile mCherry–SNRPN foci were observed
(Movie 1). In common with the SNRPB vesicles, these stained
Fig. 1. SNRPN exhibits similar behaviour to SNRPB in SH-SY5Y cells. (A) SH-SY5Y cells transiently expressing YFP–SNRPN and fixed after 24, 48 and 72 h
show variations in distribution of the YFP–SNRPN with time. Immunostaining with Y12 (detecting Sm proteins, red on overlay) and anti-coilin (white on overlay)
shows splicing speckles (chevron arrowheads) and cajal bodies (CBs, triangular arrowheads) respectively. Images are deconvolved z-stacks with 0.2 µm
spacing. (B) After transient expression, SNRPN initially localises diffusely in the cytoplasm, before localising to speckles at the 48 and 72 h time-points. Results
are mean±s.d. from three independent experiments, n=100 cells per experiment. (C) Western blot analysis of snRNPs immunoprecipitated using TMG beads
(against the characteristic tri-methyl guanosine Cap of snRNAs, left hand lane) confirms that both YFP–SNRPN (detected with anti-YFP, top row) and mCherry–
SNRPN (detected with anti-mCherry, bottom row) are incorporated into snRNPs. (D) mCherry–SNRPN cytoplasmic structures are mobile and stain with the
lipophilic dye BODIPY 493. Chevron arrowheads identify mCherry–SNRPN structures stained with BODIPY 493; triangular arrowheads identify BODIPY 493-
stained vesicles not containing mCherry–SNRPN. mCherry alone does not accumulate in BODIPY 493-stained vesicles. Cells were imaged approximately every
4 s for 9 min. Images are single deconvolved z-sections. (E) mCherry–SNRPN and GFP–SMN colocalise in cytoplasmic foci in SH-SY5Y cells (chevron
arrowheads in left hand panels), whereas YFP alone shows no accumulation in mCherry-SNRPN foci (triangular arrowheads in right hand panels). White signal
on the overlay indicates areas of colocalisation. Images are single deconvolved z-sections. (F) Comparison of the percentage of mCherry–SNRPN vesicles per
cell colocalising with GFP–SMN to those showing co-incidental overlap with YFP alone confirms the colocalisation. Results are mean±s.d., n=5 (P<0.0001,
unpaired two-tailed t-test). Scale bars: 7 µm.
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positive with the lipophilic dye BODIPY 493, indicating that they
are vesicular in nature (Fig. 1D). Finally, to confirm that the
mCherry–SNRPN vesicles were similar to those previously
identified with SNRPB, SH-SY5Y cells constitutively expressing
mCherry–SNRPN were transfected with plasmids to express either
GFP–SMN or YFP alone. GFP–SMN colocalised with mCherry–
SNRPN in 83% (±11, s.d.) of SNRPN-positive vesicles, which
is statistically significant when compared to 8.4% (±4.5) of
mCherry–SNRPN vesicles colocalising with YFP alone (Fig. 1E,F).
Mass spectrometry reveals similarities between the
interactomes of SNRPN and SNRPB
As SNRPN appeared to behave very similarly to SNRPB in neural
cells, it was unclear why neural cells express two almost identical
proteins. We decided to investigate whether SNRPN and SNRPB
may have differing roles that could be identified by proteomic
analysis. SH-SY5Y cells were selected for this analysis as they are
easy to culture and amenable to the generation of cell lines
constitutively expressing fluorescent protein-tagged proteins, while
retaining neural characteristics including the expression of neural
proteins. They are also human in origin. Proteins interacting with
YFP–SNRPB and YFP–SNRPN were affinity purified by means of
GFP-TRAP (Chromotek) from whole-cell lysates of SH-SY5Y cell
lines constitutively expressing the tagged proteins, with a cell line
expressing YFP alone as a control for non-specific binding to the tag
or bead matrix. Immunoblot analysis using antibodies to YFP
demonstrated that the enrichment of the tagged proteins was 20×,
23× and 4× for YFP–SNRPN, YFP–SNRPB and YFP alone,
respectively (Fig. 2A). The affinity purified material was size
separated by SDS-PAGE and analysed by nano-liquid
chromatography electrospray ionisation tandem mass
spectrometry (nLC ESI MS/MS) to identify peptides and, hence,
proteins interacting with YFP–SNRPB and YFP–SNRPN.
Following removal of likely contaminants identified by their
interaction with YFP alone, or their previous identification as
common contaminants in GFP-TRAP experiments (Trinkle-
Mulcahy et al., 2008), UniProt Biological Process and Cellular
Component Genome Ontology annotations were used to group
identified proteins into categories depending on function. These
groups were then used to determine whether there were differences
in possible functions between SNRPN and SNRPB (Fig. 2B)
despite their similarity (Fig. 2C). Numerous proteins previously
established to interact with Sm proteins were identified, including
SMN and the gemins as well as the methylosome components
PRMT5, MEP50 (also known as WDR77) and pICIn (also known
as CLNS1A), validating our approach (Table S1). The overall
proportions of proteins in each category were similar when
comparing the interactomes of SNRPN to SNRPB, although
differences were identified at the level of individual proteins. Of
particular interest in the context of SMAwere a number of proteins
with potential neural-specific roles, which were identified in one or
both samples. One of these was NCDN, a relatively poorly
characterised neural protein, which was identified in the YFP–
SNRPN interactome, with five unique peptides identified (Fig. 2D).
Neurochondrin interacts with SNRPN, SNRPB and SMN in
cell lines and in vivo
To verify the interaction between Sm proteins and NCDN, a
construct expressing NCDN–GFP was generated. Affinity
purification of NCDN–GFP from whole-cell lysates of SH-SY5Y
cells transiently co-expressing NCDN–GFP and mCherry–SNRPB
demonstrated interaction between NCDN–GFP and mCherry–
SNRPB (Fig. 3A). To further investigate interactions between
NCDN and the Sm proteins in neural cells, an SH-SY5Y cell line
constitutively expressing NCDN–GFP was established. Affinity
purification of NCDN–GFP from whole-cell lysates followed by
immunoblot analysis using antibodies against endogenous SNRPN
and SNRPB (Fig. 3B) revealed that NCDN–GFP interacts with both
SNRPN and SNRPB. Furthermore, both endogenous SMN and
endogenous βCOP (a coatomer vesicle protein; also known as
COPB1) were also revealed to interact with NCDN–GFP,
suggesting that NCDN interacts with the Sm proteins and SMN in
the context of cytoplasmic vesicles. Affinity purification of YFP
alone from whole-cell lysates of an SH-SY5Y cell line
constitutively expressing YFP does not result in co-purification of
endogenous SMN, SNRPB or βCOP (Fig. 3C). To further
investigate the interaction between SMN and NCDN observed in
Fig. 3B, a reciprocal experiment was performed using GFP-TRAP
to affinity purify GFP–SMN from an SH-SY5Y cell line
constitutively expressing GFP–SMN (Clelland et al., 2009).
Subsequent immunoblot analysis using antibodies to endogenous
NCDN demonstrated that NCDN co-enriched with GFP–SMN
(Fig. 3D). To determine whether this interaction also occurs
between the endogenous proteins at normal expression levels, we
first immunoprecipitated endogenous SMN from whole-cell lysates
of SH-SY5Y cells. Immunoblot analysis using antibodies against
endogenous NCDN (Fig. 3E) confirmed that endogenous SMN
interacts with endogenous NCDN. Moreover, to determine whether
this interaction is also present at endogenous levels in vivo, and thus
of potential relevance to SMA pathology, SMN was immuno-
precipitated from lysates of post-natal day (P)8 mouse brain. Again,
we confirmed that endogenous SMN interacts with endogenous
NCDN in vivo (Fig. 3F). Taken together, these results confirm the
interaction of SMN and NCDN at endogenous levels and in vivo.
Neurochondrin colocalises with SNRPN, SNRPB and SMN in
cytoplasmic vesicles but not nuclear foci and is strongly
expressed in motor neurons in mouse spinal cord
To determine the probable cellular location for the interaction
between SNRPN or SNRPB and NCDN, plasmids to express either
NCDN–GFP or YFP were transiently transfected into SH-SY5Y
cells constitutively expressing mCherry–SNRPN. This revealed that
NCDN–GFP, but not YFP alone, accumulates in cytoplasmic
vesicles containing mCherry–SNRPN (Fig. 4A). Similar results
were obtained when NCDN–GFP was transiently expressed
in SH-SY5Y cells constitutively expressing mCherry–SNRPB
(Fig. S2). To investigate the probable cellular location of
interactions between SMN and NCDN, mCherry–SMN was co-
expressed with either NCDN–GFP or YFP alone. NCDN–GFP was
found in cytoplasmic structures enriched in mCherry–SMN
(Fig. 4B). These data suggest that NCDN colocalises with both
the Sm proteins and SMN in cytoplasmic vesicles, although
NCDN–GFP has a higher level of diffuse signal than the Sm
proteins or SMN. Within the nucleus, antibodies to endogenous
NCDN showed very little nuclear staining, with nuclear foci evident
in very few cells (≤2%). These foci did not stain with antibodies to
either coilin or SMN (Fig. 4C) indicating that they are neither CBs
nor gems. In sections from murine P5 spinal cord (Fig. 4D,E),
NCDN shows robust expression throughout the spinal cord.
Interestingly, NCDN was most prominently expressed in choline
acetyltransferase (ChAT)-positive motor neurons in the ventral horn
of the spinal cord (arrows in Fig. 4D, enlarged in Fig. 4E). This
indicates that NCDN is enriched in motor neurons: the most relevant
cell type for SMA.
4
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs211482. doi:10.1242/jcs.211482
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
Fig. 2. The interactomes of SNRPB and SNRPN are similar, but there are differences at the level of individual proteins. (A) Immunoblot analysis confirms
efficient affinity purification of YFP–SNRPN, YFP–SNRPB and YFP. 10% of the affinity purified material (left hand lane in each panel) was compared to 80 µg
of precleared lysate (Input) and unbound material using anti-GFP antibody. GFP-Trap effectively immunoprecipitated all three proteins. (B) After processing
the MS data and sorting identified proteins into groups based on Gene Ontology annotations, the interactomes of SNRPN and SNRPB are very similar.
(C) A comparison between the amino acid sequences of SNRPN and SNRPB reveals their similarity. Differences in amino acid sequence are in red. Sequences
are from Uniprot [entries P63162 (SNRPN) and P14678-2 (SNRPB)]. (D) NCDN was identified in the interactome of YFP–SNRPN, with five unique peptide
hits encompassing 9% sequence coverage. Each Ion score (Mascot Ion Score) was above the threshold for peptide identity (Mascot Identity Score), with two out
of the five identified peptides having a score of above double the threshold score.
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NCDN, SMN and Sm proteins co-fractionate with coatomer
proteins
To further investigate the possibility that the interaction of NCDN
with SMN and the Sm proteins occurs within cytoplasmic vesicles,
subcellular fractionations were performed on both parental SH-
SY5Y cells and SH-SY5Y cell lines constitutively expressing
NCDN–GFP, YFP–SNRPB, YFP–SNRPN or YFP. Sequential
centrifugation was used to separate the cells into a nuclear fraction,
16,000 g and 100,000 g cytoplasmic pellets, and cytosolic
supernatant (De Duve, 1971). Immunoblotting of these
subcellular fractions revealed that GFP–NCDN, YFP–SNRPB
and YFP–SNRPN, were all enriched in the 100,000 g
cytoplasmic pellet, along with endogenous SMN and coatomer
proteins (Fig. 5). This fraction would be expected to contain
membrane-bound structures, such as microsomes and small
cytoplasmic vesicles, which would encompass small coatomer-
type endocytic vesicles. Endogenous SNRPN was also observed to
enrich similarly (Fig. S3). A larger proportion of NCDN–GFP
remained in the cytosolic supernatant than did YFP–SNRPB, YFP–
SNRPN and endogenous SMN, which is in agreement with the
subcellular localisations observed (Fig. 4). This further supports our
hypothesis that the interactions between NCDN, SMN and the Sm
proteins take place in small cytoplasmic vesicles.
NCDN is required for the correct subcellular localisation
of SMN
We have previously documented that reduction of SNRPB
expression results in re-localisation of SMN into numerous
nuclear structures, probably analogous to gems (gemini of CBs),
and its loss from cytoplasmic structures (Prescott et al., 2014). To
investigate the requirement for NCDN in cytoplasmic SMN
localisation, an SH-SY5Y cell line constitutively expressing
GFP–SMN (Clelland et al., 2009) was transfected with siRNAs
targeting NCDN [four different single siRNAs (Dharmacon) and a
pooled sample]. A reduction in NCDN expression caused an
increase in the number of SMN-positive nuclear foci present in the
cell nucleus, as did a reduction of SNRPB expression (Fig. 6A,B).
Conversely, reduction in SMN expression reduced the number of
SMN-positive nuclear foci. The use of non-targeting control
(siControl) sequences or positive control siRNAs (targeting lamin
A/C) had no effect on the number of SMN-positive nuclear foci.
The reduction in gene expression, as assayed by immunoblotting,
for each siRNAwas typically 40–60% (Fig. 6C). This suggests that
NCDN is required for the correct sublocalisation of SMN. Of
potential relevance for SMA pathology, depletion of either NCDN
or SNRPB causes GFP–SMN to adopt a subcellular localisation
reminiscent of that shown by GFP–SMNΔ7 (Fig. 6), a truncated
version of SMN that mimics the product of the SMN2 gene and is
unable to completely substitute for full-length SMN in models of
SMA (Le et al., 2005; Monani et al., 1999, 2000).
SMN is required for the correct subcellular localisation
of NCDN
To investigate whether NCDN requires the SMN protein for its
localisation to vesicles in neural cells, SH-SY5Y cells were
transfected with shRNA constructs previously validated to reduce
the expression of SMN by an average of 46%, a reduction
previously found to cause symptoms resembling SMA type III in
mouse models (Jablonka et al., 2000), and carrying a GFPmarker to
unequivocally identify transfected cells (Clelland et al., 2012).
Reduction of SMN, monitored by quantification of the number of
SMN-positive nuclear foci (Fig. 7A,C), reduced the number of
cytoplasmic foci containing endogenous NCDN (Fig. 7A,B). This,
together with data in Fig. 6, suggests that NCDN and SMN are
mutually dependent for their incorporation into cytoplasmic
structures, raising the possibility that the lowered levels of SMN
seen in SMA could compromise NCDN function.
NCDN does not co-purify with splicing snRNPs, suggesting it
is not involved in snRNP assembly
To investigate whether the interaction between NCDN and SMN
could reflect a previously unidentified role for NCDN in snRNP
assembly, splicing snRNPs were affinity purified from whole-cell
lysates of SH-SY5Y cells constitutively expressing NCDN–GFP
using agarose beads coupled to antibodies against the characteristic
tri-methyl guanosine Cap of snRNAs (TMG beads, Millipore)
(Fig. 8A). Endogenous SNRPN protein showed strong enrichment
in the affinity purified snRNP samples, as expected for a core
snRNP protein. Endogenous SMN was also co-enriched with
snRNPs, demonstrating that the experimental conditions were
suitable to identify proteins important for snRNP assembly as well
as those that are genuine snRNP components. NCDN–GFP did not
co-purify with splicing snRNPs, however, suggesting that NCDN is
not involved in snRNP assembly or processing. This raises the
intriguing possibility that the interaction between SMN and NCDN
reflects a novel, snRNP-independent role for SMN.
Fig. 3. NCDN interacts with SNRPN, SNRPB and SMN in cell lines and in
mice. (A) Affinity isolation of NCDN–GFP using GFP-Trap, detected with anti-
GFP antibody (top row) co-enriches mCherry–SNRPB, detected with anti-
mCherry (bottom row) in transiently co-transfected SH-SY5Y cells. (B) In an
SH-SY5Y cell line constitutively expressing NCDN–GFP, affinity isolation of
NCDN–GFP, detected with anti-GFP antibody (top row) co-enriches SMN,
SNRPB, SNRPN and the coatomer protein βCOP, all detected with antibodies
against the endogenous proteins (as labelled). (C) In an SH-SY5Y cell line
constitutively expressing YFP, affinity isolation of YFP, detected with anti-GFP
antibody (top row) does not co-enrich SMN, SNRPB or βCOP, all detected with
antibodies to the endogenous proteins (as labelled). (D) In an SH-SY5Y cell
line constitutively expressing GFP–SMN, affinity isolation of GFP–SMN,
detected with anti-GFP antibody (top row) co-enriches endogenous NCDN,
detected with anti-NCDN antibody (middle row). Endogenous SMN, detected
with anti-SMN (bottom row) is also co-enriched. (E) Immunoprecipitation (IP)
of endogenous SMN co-enriches endogenous NCDN in SH-SY5Y cells.
(F) Immunoprecipitation of endogenous SMN from murine P8 brain lysate
co-enriches NCDN.
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SMN interacts with Rab5 in SH-SY5Y cells and colocalises
with a sub-set of Rab5 vesicles
Recent studies have found that SMA may cause endocytic defects,
especially in synaptic vesicle recycling in animal models
(Dimitriadi et al., 2016). Several SMA-protective disease modifier
genes, such as plastin 3, coronin 1C and neurocalcin δ, are also
associated with endocytosis (Hosseinibarkooie et al., 2016; Oprea
et al., 2008; Riessland et al., 2017). However, other endocytic
Fig. 4. NCDN colocalises with SNRPN and SMN in the cytoplasm, but not the nucleus, and is expressed in motor neurons in mouse spinal cord.
(A) NCDN–GFP and mCherry–SNRPN colocalise in vesicle-like structures (chevron arrowheads) in neurites of SH-SY5Y cells constitutively expressing
mCherry–SNRPN, and transiently expressing NCDN-GFP (left hand panels). White areas in the merged image show areas of colocalisation. Colocalisation
images (bottom row) were generated in Volocity, using automatic thresholds on undeconvolved z-sections before excluding values below 0.05 (seeMaterials and
Methods). No colocalisation is seen in the same cell line transiently expressing YFP alone (right hand panel). Triangular arrowheads show structures containing
mCherry–SNRPN but not YFP. (B) mCherry–SMN and NCDN–GFP colocalise in vesicles (chevron arrowheads) in the cytoplasm of co-transfected SH-SY5Y
cells (left hand panels). White areas in the merged image show areas of colocalisation. Colocalisation images (bottom row) were generated as above. No
colocalisation is observed between mCherry-SMN and YFP (triangular arrowheads, right hand panels). (C) NCDN forms nuclear foci (arrows) in the nuclei of a
small proportion of SH-SY5Y cells (≤2%, two independent experiments, n=100 cells per experiment). These do not colocalise with nuclear foci stained with coilin
(arrowheads, left hand panels) or SMN (arrowheads, right hand panels). (D) NCDN (green) is expressed throughout the spinal cord, with increased expression in
motor neurons (arrows), as identified with anti-ChAT antibody (magenta). (E) Higher magnification imaging confirms the presence of NCDN in ChAT-positive
motor neurons (single deconvolved z-section). Scale bars: 7 µm (A,B); 500 µm (C,D); 10 µm (E).
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structures within the cell have not been investigated. Rab5 (which
has two forms, Rab5a and Rab5b) is a marker of early endosomes
and endocytic vesicles, as well as being a regulator of these
trafficking pathways (Bucci et al., 1992). NCDN and Rab5 have
previously been shown to interact, while both Rab5 and NCDN both
have roles in dendrite morphogenesis and cell polarity (Guo et al.,
2016; Oku et al., 2013; Satoh et al., 2008).
As we have shown above that SMN and NCDN colocalise in
vesicles, we hypothesised that some of the SMN-rich vesicles could
be Rab5 vesicles. SH-SY5Y cells were co-transfected with plasmids
to express mRFP–Rab5 (the Rab5a form) (Vonderheit and Helenius,
2005) together with either GFP–SMN, NCDN–GFP or YFP. mRFP–
Rab5 was affinity-purified from whole-cell lysates from each
co-transfection by using RFP-TRAP (Chromotek). Subsequent
immunoblotting revealed co-purification of GFP–SMN and
NCDN–GFP, but not YFP alone, with mRFP–Rab5 (Fig. 8B).
Furthermore, endogenous SMN also co-purified with mRFP–Rab5.
In parallel experiments, colocalisation of mRFP–Rab5 with GFP–
Fig. 5. Detergent-free fractionation of SH-SY5Y cells reveals that SMN, coatomer proteins, NCDN, SNRPB and SNRPN are all enriched in the 100,000 g
vesicle pellet. (A) Immunoblotting of equal protein amounts from fractionated SH-SY5Y cells reveals that SMN (top row) is highly enriched in the 100,000 g
(RCF) pellet (small membrane-bound structures), with smaller amounts seen in the 16,100 g pellet (larger membrane-bound structures) and the nuclear pellet.
The coatomer protein, γCOP (also known as COPG1; second row) is also enriched in the 100,000 g pellet as well as the 16,100 g pellet. Antibodies against
histone H3 and tubulin confirm minimal nuclear contamination in cytoplasmic fractions, and minimal cytoplasmic contamination in the nuclear pellet, respectively.
(B) Quantification of immunoblot analysis confirms that SMN is highly enriched in the 100,000 g pellet, with enrichment of γCOPalso seen. Histone H3 and tubulin
are highly enriched in the nucleus and cytoplasm, respectively. Quantification (mean±s.d.) of tubulin and histone H3 band density was from seven immunoblots,
with values from SMN and γCOP from five and four immunoblots, respectively. (C) Immunoblotting of equal protein amounts from fractionated SH-SY5Y cells
constitutively expressing NCDN–GFP, YFP–SNRPB, YFP–SNRPN or YFPalone (all detectedwith anti-GFPantibody) reveals that NCDN–GFP is enriched in the
100,000 g pellet, with smaller amounts seen in the 16,100 g pellet and the cytosolic supernatant. YFP–SNRPB and YFP–SNRPN are both also found in the
100,000 g pellet, in addition to the nuclear pellet and cytosolic supernatant. YFPalone is found almost exclusively in the cytosolic supernatant, with none detected
in the 100,000 g or 16,100 g pellets. (D) Quantification of the band densities for the immunoblot shown in C confirms the presence of NCDN–GFP, YFP–SNRPB
and YFP–SNRPN in the 100,000 g pellet, together with the restriction of YFP alone to the residual cytosolic supernatant.
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Fig. 6. See next page for legend.
9
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs211482. doi:10.1242/jcs.211482
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
SMN and NCDN was investigated (Fig. 8C,D). In accordance with
previous publications, Rab5 showed partial colocalisation with
NCDN–GFP in cytoplasmic structures (arrows in Fig. 8D) (Oku
et al., 2013). GFP–SMN showed a similar degree of colocalisation
with mRFP–Rab5, also in cytoplasmic structures, while there was
minimal colocalisation between YFP and mRFP–Rab5. Taken
together with the absence of NCDN from enriched snRNP
fractions (Fig. 8A), this suggests that NCDN and SMN colocalise
in the context of Rab5 vesicles, independently of snRNP assembly.
DISCUSSION
The genetic cause of SMA has been known since 1995 (Lefebvre
et al., 1995), but there is still little available in the way of treatment.
Spinraza/Nusinersen is now available to treat SMA by correcting the
defective splicing of the SMN2 transcript to promote production of
full-length SMN protein. However, this is not a complete cure and
requires regular maintenance doses through intrathecal injection.
Additionally, little has been done to investigate potential symptoms
that could arise later in life or in other tissues and organs in patients
treated with Spinraza. Additional treatment options for SMA are still
needed for use in addition to Spinraza, or in place of it for patients
for whom it is not suitable, including those with rarer forms of SMA
in which SMN1 is not mutated.
A significant reason for the lack of treatment options for SMA is
uncertainty about the cellular roles of SMN, which appear to be
numerous. In particular, it is not clear why motor neurons are so
exquisitely sensitive to reduced levels of SMNwhen the key roles of
the protein appear to be in pathways required in all cell types. By
comparing the interactomes of two very similar members of Sm
protein family, SNRPB and the neural-specific SNRPN, we have
uncovered an interaction between SMN and the essential neural
protein NCDN, which may be of relevance for SMA pathology and
have the potential to open novel avenues for therapy development.
The neural-specific Sm protein SNRPN behaves similarly to
SNRPB, but shows subtle differences at the interactome
level that may indicate alternative roles
Differences between members of the Sm protein family have not
been systematically investigated, although non-splicing roles have
been proposed for SNRPB and SNRPD3 in mRNA localisation,
and for SNRPD1 in miRNA biogenesis, in Drosophila (Gonsalvez
et al., 2010; Xiong et al., 2015). As SNRPB and SNRPN are thought
to perform the same primary function in snRNPs (Huntriss et al.,
1993), it is currently unknown why SNRPN is expressed in neural
tissues as well as, or instead of, SNRPB. Current research has
suggested that the expression of SNRPN may cause tissue-specific
alternative splicing of pre-mRNA transcripts (Lee et al., 2014).
However, an alternative, but complementary hypothesis is that
SNRPN may be adapted for secondary neural-specific roles. We
demonstrate here that SNRPN localises identically to SNRPB
during snRNPmaturation and at the steady-state, when both localise
to vesicles containing SMN in the cytoplasm and neurites of
SH-SY5Y cells in addition to their canonical localisation to nuclear
CBs and speckles. Our parallel proteomic study used SH-SY5Y
neural cell lines constitutively expressing YFP–SNRPN and
YFP–SNRPB to investigate differences between the interactomes
of these two, very similar, proteins. SNRPN has a proline-rich
C-terminal tail that SNRPB lacks, although a similar sequence is
present in SNRPB′ (Mourao et al., 2016), an alternatively spliced
product of the SNRPB gene. Several proteins were identified in the
SNRPN interactome but not the SNRPB interactome, such as
nuclear receptor co-activator 6 interacting protein (UniProt
Q96RS0), and 7SK snRNA methylphosphate capping enzyme
(UniProt Q7L2J0), both of which are associated with snRNA
capping (Hausmann et al., 2008; Jeronimo et al., 2007).
Additionally, RNA-binding protein 40 (UniProt Q96LT9) was
uniquely identified within the SNRPN interactome, and is involved
in the minor spliceosome (Benecke et al., 2005). This suggests that
some of these proteins may interact preferentially with SNRPN,
perhaps mediated by amino acid changes within the proline-rich tail.
However, further validation and additional experimentation would
be required to confirm these differences in interactome between
SNRPN and SNRPB, and to investigate specific functions for the
distinct Sm protein family members.
NCDN interacts with SMN, SNRPB and SNRPN and
colocalises with them in vesicles, suggesting a novel
cellular role for SMN
Previous research into neural-specific functions for SMN has
identified several new protein–protein interactions involving SMN.
These novel SMN partners have, in the main, been RNA-binding
proteins (Akten et al., 2011; Fallini et al., 2014, 2011; Rossoll et al.,
2003). There is growing appreciation that SMN-mediated transport
may be of particular importance in neural cells and involve COPI-
type vesicles transported by dynein and containing SNRPB (Custer
et al., 2013; Li et al., 2015; Peter et al., 2011; Prescott et al., 2014).
The nature and content of these vesicles is not clear but they are
likely to be of significance for the cell-type bias of SMA symptoms,
as they are present predominantly in neural cells (Akten et al., 2011;
Fallini et al., 2016, 2014, 2011; Li et al., 2015; Peter et al., 2011;
Prescott et al., 2014; Rossoll et al., 2003; Todd et al., 2010a,b;
Fig. 6. Reduction of endogenous NCDN through siRNA increases
localisation of SMN to nuclear foci. (A) Transfection of SH-SY5Y cells
constitutively expressing GFP–SMN (green) with siRNAs shows an increase in
the number of SMN-positive nuclear foci (arrowheads) in cells transfected with
siRNAs against NCDN (siNCDN, pooled represents all four siRNA molecules
together) or SNRPB (siSNRPB), and a decrease in the number of SMN-positive
nuclear foci in cells transfected with siRNAs against SMN (siSMN) in comparison
to cells transfected with non-targeting siRNAs (siControl) or siRNAs against
lamin A/C (siLamin A/C) as a ‘targeting’ control. Transfection of SH-SY5Y cells
with a plasmid to express GFP–SMNΔ7 also results in increased numbers of
SMN-positive nuclear foci. Cell nuclei are stained with Hoechst 33342 (grey on
images). Transfection efficiency with siRNAs was greater than 90%, measured
by transfection with siGlo Cyclophillin B (data not shown). Scale bars: 7 µm.
Images are deconvolved z-stacks takenwith 0.2 µmspacing. (B)Quantification of
numbers of SMN-positive nuclear foci per nucleus showing that there is a
significant increase following reduction of NCDN [10.2 (±4.1) with siNCDN 18,
10.4 (±5.0) with siNCDN 19, 9.9 (±4.1) with siNCDN 20, 9.5 (±3.6) with siNCDN
21, and 10.7 (±4.6) with siNCDN pooled] compared to 4.4 (±2.5) in cells treated
with non-targeting siRNA (siControl) and 4.2 (±2.3) in cells treated with siRNAs
targeting lamin A/C (siLaminA/C). Reduction of SNRPB also shows an increase
in numbers of SMN-positive nuclear foci [to 16.7 (±6.8) with siSNRPB], while
reduction of SMN leads to a decrease in numbersof SMN-positive nuclear foci [to
0.7 (±1.4) with siSMN]. Expression of GFP–SMNΔ7 results in an increase of
numbers of SMN-positive nuclear foci to 18.2 (±5.3). All values are mean±s.d.
The difference between each siNCDN and controls is statistically significant
(AVOVA; P<0.0001, n=150 from 3 replicates). The box represents the 25–75th
percentiles, and themedian is indicated. Thewhiskers show the range of the data
excluding outliers identified by the Tukey method. A Tukey post-test identified
outliers (individual points marked on graph). (C) Immunoblot analysis using
antibodies to endogenous NCDN, SMN and SNRPB shows a reduction in
expression of each of 40–60% compared to siControl cells, after signals were
normalised to tubulin (also see Fig. S4). Reductions in protein expression
(mean±s.d.) compared to siControl siRNA are statistically significant (ANOVA;
P<0.0001 for NCDN, Lamin A/C and endogenous SMN; P<0.001 for SNRPB;
P<0.01 for GFP–SMN, n=3). A Dunnett post-test identified the significance of the
reduction compared to siControl. *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001.
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Zhang et al., 2006, 2003). The SNRPN/SNRPB interactome screen
presented here suggests a large number of non-snRNP proteins as
potential cellular partners for the Sm proteins.
We chose to investigate the neural protein NCDN further, as it has
characteristics that may be of relevance for SMA. NCDN is
predominantly expressed in neural tissue, and little is known about
its structure or function, as it shares little sequence similarity to
other eukaryotic proteins (Shinozaki et al., 1997). Although
characterised relatively poorly, it is associated with dendrite
morphogenesis and localises to Rab5 vesicles, which are involved
in the maintenance of cell polarity (Guo et al., 2016; Oku et al.,
2013). NCDN has also been demonstrated to regulate localisation of
signalling proteins such as P-Rex 1 (Pan et al., 2016), suggesting
that it, in common with SMN, has a role in intracellular trafficking.
These neural-specific and trafficking roles suggest that further
analysis of the interaction between NCDN and the Sm proteins
might lead to better understanding of the molecular mechanisms of
pathogenesis in SMA.
Reciprocal affinity-purification of GFP-tagged and
endogenous NCDN and Sm proteins (Fig. 3A,B) validated the
interaction detected in the interactome analysis. Although
originally identified as a protein interacting with SNRPN but
not SNRPB, further investigation indicates that NCDN is, in fact,
capable of interacting with both of these Sm proteins. Of much
greater interest, however, is the interaction documented between
NCDN and SMN, which appears more robust than that between
NCDN and the Sm proteins (Fig. 3). Furthermore, NCDN
localises with SMN and the Sm proteins in mobile vesicles in the
neurites of SH-SY5Y cells (Fig. 4), rather than in the nucleus,
suggesting that it shares cytoplasmic, rather than nuclear, roles
with SMN. The truncated protein SMNΔ7, which cannot fully
substitute for full-length SMN despite retaining some
functionality, is largely restricted to the nucleus (Renvoise
et al., 2006; Sleigh et al., 2011). While it cannot yet be ruled out
that SMNΔ7 lacks the capability to substitute for full-length
SMN in nuclear roles, this suggests that cytoplasmic roles of
Fig. 7. Reduction of endogenous SMN causes a reduction in cytoplasmic NCDN foci in SH-SY5Y cells. (A) SH-SY5Y cells were transfected with plasmids to
express shRNAs targeting SMN (shSMN), Cyclophilin B (shCyclophilin) or with the empty pSuper GFP vector (data not shown), fixed after 72 h, and immunostained
for endogenous NCDN and SMN allowing detection of NCDN foci within the cytoplasm (chevron arrowheads), as well as SMN-positive nuclear gems
(triangular arrowheads). Images are single deconvolved z-sections. Scales bars: 7 µm. (B) The depletion of SMN results in a reduction in the number of NCDN foci
present in the cytoplasm to 15.3 (±7.2) (mean±s.d.) from 20.6 (±12.0) and 19.5 (±7.6) compared to cells transfected with either shCyclophilin B or the empty
pSuperGFPvector, respectively (ANOVA,P<0.0005,n=64 from3 replicates). Thebox represents the 25–75th percentiles, and themedian is indicated. Thewhiskers
show the range of the data excluding outliers identified by the Tukeymethod. Outliers are shown as individual points. (C) The depletion of SMN causes a reduction of
nuclear gems to 0.17 (±0.38) from 2.3 (±0.84) or 3.0 (±1.0) compared to cells transfected with shCyclophilin B or empty vector respectively confirming efficient
reduction in SMN protein levels. Results are mean±s.d. (n=30 from three replicates). *P≤0.05, **P≤0.01, ***P≤0.001, ****P≤0.0001 (ANOVA).
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SMN are key to SMA pathology. NCDN was not co-purified
with splicing snRNPs, under conditions that showed a clear
enrichment of SMN, a key assembly factor for snRNPs, in the
snRNP fraction. This suggests that the interaction between
NCDN, SMN and the Sm proteins is not related to snRNP
assembly.
Fig. 8. NCDN does not co-purify with snRNPs, while NCDN and SMN interact with Rab5 and colocalisewith a subset of Rab5 vesicles within neurites of
SH-SY5Y cells. (A) Incubation of whole-cell lysate from an SH-SY5Y cell line constitutively expressing NCDN–GFPwith agarose beads conjugated to antibodies
against the tri-methyl guanosine cap (Me3Gppp) of snRNAs (TMG beads) affinity purifies snRNPs as evidenced by the enrichment of the core snRNP
protein SNRPN (detected with anti-SNRPN antibody, bottom row). The enriched snRNP fraction also contains SMN, which is essential for snRNP assembly.
NCDN–GFP, however, does not co-enrich with snRNPs. Also shown is the core structure of mature snRNPs consisting of the heptameric Sm protein ring bound at
the Sm-binding site of snRNA, as well as the characteristic tri-methyl guanosine Cap of snRNAs (Me3Gppp) at the 5′ end. (B) Affinity isolation of mRFP–Rab5
using RFP-Trap from cells co-transfected with plasmids to express mRFP–Rab5 together with NCDN–GFP, GFP–SMN or YFP alone co-enriches both
NCDN–GFP (top row, detected with anti-GFP antibody, band is present in RFP-Trap lane but not Sepharose beads lane) and SMN-GFP (second row, detected
with anti-GFP antibody, band is present in RFP-Trap lane but not Sepharose beads lane), but not YFP (third row, no band detected in RFP-Trap lane).
Endogenous SMN (fourth row, detected with mouse anti-SMN) co-enriches with mRFP–Rab5 in all three samples. Detection of mRFP–Rab5 (bottom row,
detected with anti-RFP antibody) confirms substantial enrichment of mRFP–Rab5 in all three samples. (C) Both GFP–SMN and NCDN–GFP partially colocalise
with mRFP–Rab5 in a subset of mRFP–Rab5-containing vesicles in co-transfected SH-SY5Y cells (white signal in overlaid images, top row; yellow signal in
colocalisation images, bottom row). (D) Enlargement of the boxed areas in C confirms that the colocalisation between SMN or NCDN andRab5 occurs in punctate
structures. Arrowheads identify areas of colocalisation. Colocalisation images were generated by Volocity using automatic thresholds on non-deconvolved
z-sections before excluding values below 0.05. Images (excluding the colocalisation images) are single deconvolved z-sections. Scale bars: 7 µm.
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Potential consequences of NCDN mis-localisation
associated with SMN reduction
We have identified colocalisation of both SMN and NCDN with a
subset of Rab5 vesicles. Since NCDN is also found in a subset of
SMN-positive cytoplasmic structures, it is highly likely that these are
Rab5 vesicles. It is possible that the protein–protein interactions
between NCDN and SMN occur elsewhere in the cytoplasm as both
proteins also show a diffuse cytosolic pool, but the decrease seen in
cytoplasmic structures containing NCDN following SMN depletion
suggests that cellular pathways requiring NCDN-containing vesicles
may be compromised in SMA. Loss of NCDN-positive cytoplasmic
structures was seen in cells with a moderate reduction in SMN levels,
so NCDNmay be of relevance for patients withmilder forms of SMA.
At present, the precise roles of NCDN are not fully understood,
although it has been implicated in dendrite morphogenesis, neural
outgrowth, synaptic plasticity regulation and moderation of
signalling pathways in neural cells (Dateki et al., 2005; Francke
et al., 2006; Matosin et al., 2015; Ohoka et al., 2001; Oku et al.,
2013; Pan et al., 2016; Shinozaki et al., 1999, 1997; Wang et al.,
2013, 2009; Ward et al., 2009). NCDN has also previously been
shown to localise to Rab5 vesicles within dendrites (Oku et al.,
2013). These dendritic Rab5 vesicles have been found to have an
important role in dendrite morphogenesis and somatodendritic
polarity (Guo et al., 2016; Satoh et al., 2008). As we have now
demonstrated that SMN localises to a subset of Rab5 vesicles, likely
in association with NCDN, SMN may also be implicated in cell
polarity, with an insufficiency of SMN causing problems with both
establishment and maintenance of polarity. These would be
particularly vital in such elongated cells as motor neurons and
may be mediated through trafficking of mRNAs or proteins. Further
work will be required to investigate defects in cell polarity as a
pathogenic mechanism in SMA and their possible link to NCDN.
NCDN as a potential novel therapeutic target in SMA
SMN has now been linked to several functions other than its
canonical role in snRNP assembly.While reduction in the capacity
of the cell for snRNP assembly caused by lowered SMNmay cause
splicing defects, the key transcripts preferentially affecting motor
neurons are still to be identified. SMN has an established role in
the trafficking of mature mRNAs destined for localised translation.
The nature of the structures involved in this role is not completely
clear, however, with different authors describing the structures as
vesicular or granular. Reduction of SMN has also been linked with
endosomal defects, suggestive of the importance of SMN for
vesicular transport. Here, we provide further evidence for the
presence of SMN in, or associated with, vesicles and document
interactions between the essential neural protein, NCDN and
SMN. Together with the clear enrichment of NCDN in motor
neurons in mouse spinal cord, this suggests that NCDN may be a
downstream target of SMN reduction in SMA, and places it as a
potential target for therapy development in SMA. Further work
will be required to establish which roles of NCDN also involve
SMN, and whether these are of relevance for the molecular
pathology of SMA. The co-dependence of SMN and NCDN in
cytoplasmic vesicles, however, suggests that depletion of SMN, as
seen in the majority of SMA patients, may affect NCDN
localisation and/or function.
MATERIALS AND METHODS
Plasmid constructs
pEGFP-SMN, pEYFP-SNRPB and mCherry-SNRPB have been described
previously (Clelland et al., 2009; Sleeman et al., 2001; Sleeman and
Lamond, 1999). pEYFP-SNRPN and pmCherry-SNRPNwere generated by
PCR amplification and subcloning cDNA of human SNRPN from
SH-SY5Y cells into pEYFP-C1 and pmCherry-C1, respectively, by using
SNRPNEcoRI forward primer 5′-TAGAATTCCATGACTGTTGG-
CAAGAGTAGC-3′, and SNRPNBamHI reverse primer 5′-
TAGGATCCCTGAGATGGATCAACAGTATG-3′. pmCherry-SMN was
generated by PCR amplification and subcloning the sequence from the
pEGFP-SMN plasmid into pmCherry-C1 using an SMNEcoRI forward
primer 5′-GCGGAATTCTATGGCGATGAGC-3′ and SMNBamHI
reverse primer 5′-GCAGGATCCTTAATTTAAGGAATGTGA-3′. To
generate pEGFP-NCDN, NCDN cDNA from SH-SY5Y cells was PCR
amplified and subcloned into a pEGFP-N3 plasmid using NCDNEcoRI
forward primer 5′-GCGGAATTCATGGCCTCGGATTGCG-3′ and
NCDNSalI reverse primer 5′-GCTGCTGACGGGCTCTGACAGGC-3′.
All cDNAs were amplified using GoTaq G2 (Promega, Madison, WI) and
the PCR products restriction digested using EcoRI and either BamHI or SalI
(Promega), before ligationwith T4DNA ligase (Thermo Scientific,Waltham,
MA). mRFP-Rab5 was a gift fromAri Helenius (Institut für Biochemie, ETH
Zurich, Zürich, Switzerland) (Vonderheit and Helenius, 2005).
Cell lines and cell culture
SH-SY5Y cells were from the ATCC. Cells were cultured in DMEM with
10% FBS at 37°C, 5% CO2. Transfections were carried out using Effectene
(Qiagen, Hilden, Germany) according to the manufacturer’s instructions.
Stable SH-SY5Y cell lines expressing mCherry–SNRPB and GFP–SMN
have been described previously (Clelland et al., 2009; Prescott et al., 2014).
SH-SY5Y cell lines stably expressing YFP–SNRPN, YFP–SNRPB, YFP,
mCherry–SNRPN and NCDN–GFP were derived by clonal isolation
following selection with 200 µg/ml G418 (Roche, Basel, Switzerland)
following transfection.
Animals
Mouse tissues in this study were obtained from littermate healthy control
mice (Smn+/−; SMN2tg/0) from the ‘Taiwanese’ model of SMA (Hsieh-Li
et al., 2000). Mice were originally obtained from Jackson Laboratories and
were maintained in animal care facilities at the University of Edinburgh, UK
under standard specific pathogen-free conditions on a congenic FVB
background. All animal breeding was performed in accordance with
University of Edinburgh institutional guidelines and under the appropriate
project and personal licences granted by the UK Home Office.
Immunostaining, microscopy and image analysis
Cell fixing and immunostaining were both carried out as described
previously (Sleeman et al., 2003). Immunostaining of spinal cord sections
was carried out as described previously (Powis and Gillingwater, 2016).
Live-cell and fixed cell microscopy and image processing were carried out
as described previously (Prescott et al., 2014). BODIPY-493 (Life
Technologies, Paisley, UK) was added to culture medium at 2 µg/ml
overnight. Antibodies used for immunostaining were: mouse monoclonal
Y12 anti-Smith (SNRPB) (Abcam, Cambridge, MA, ab3138, 1:20), rabbit
polyclonal 204-10 (anti-Coilin) (a gift from Angus I. Lamond, School of
Life Sciences, University of Dundee, UK; 1:500; Bohmann et al., 1995),
mouse monoclonal anti-SMN (BD Transduction, San Jose, CA, 610646,
1:50), goat anti-ChAT (Millipore, Burlington, MA, AB144P) and rabbit
polyclonal anti-NCDN (Proteintech, Manchester, UK, 13187-1-AP, 1:50)
antibodies. Overlays of images were made using Adobe Photoshop CS5
(Adobe, San Jose, CA). Colocalisation images were generated by using
Volocity 6.3 (PerkinElmer, Waltham, MA) with automatic thresholds on
non-deconvolved images. Colocalisation values of 0.05 or less were
excluded as this was the maximum colocalisation value observed between
the mCherry signal and YFP signal in neurites expressing YFP as a control
together with mCherry-tagged proteins of interest. Deconvolution was also
performed using Volocity 6.3, with between 15 and 25 iterations of
deconvolution. Images of spinal cord sections collected using a 60×
objective on a DeltaVision RT microscope (Applied Precision) were
assembled into panels using the FIJI (Schindelin et al., 2012) plug-in and a
custom written export protocol.
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Preparation of cell lysates and immunoblotting
Cells were grown in 10 cm diameter dishes, before being detached with
trypsin and collected by centrifugation at 180 g for 5 min. The cell pellet was
washed three times in PBS before lysis in 100 µl of ice-cold lysis buffer per
dish [50 mM Tris-HCl pH 7.5, 0.5 M NaCl; 1% (v/v) Nonidet P-40, 1%
(w/v) sodium deoxycholate, 0.1% (w/v) SDS, 2 mM EDTA plus cOmplete
mini EDTA-free protease inhibitor cocktail (Roche, one tablet per 10 ml)],
followed by homogenisation by sonication. Isolation of YFP/GFP and
mCherry/mRFP-tagged proteins was carried out as described previously
with GFP- or RFP-Trap (Chromotek, Planegg-Martinsried, Germany)
(Prescott et al., 2014). Immunoprecipitation of endogenous SMN from brain
lysate was carried out as described previously by using mouse monoclonal
anti-SMN (BD Transduction Labs 610646) (Boyd et al., 2017; Groen et al.,
2013). Lysates were electrophoresed on a 10% SDS-polyacrylamide gel and
transferred onto nitrocellulose (Hybond-C+ or Protran premium 0.2 µm, both
GE Healthcare, Little Chalfont, UK) membranes for immunoblotting.
Antibodies used were rat monoclonal anti-RFP (Chromotek 5F8, 1:500);
goat polyclonal anti-γCOP (Santa CruzBiotechnology, Dallas, TX, sc-14167,
1:250), rabbit polyclonal anti-GFP (Abcam ab290, 1:2000), rabbit polyclonal
anti-SNRPN (Proteintech 11070-1-AP, 1:800), mouse monoclonal Y12 anti-
Smith (SNRPB) (Abcam ab3138, 1:100), rabbit polyclonal anti-SMN (Santa
Cruz Biotechnology, sc-15320, 1:500), mouse monoclonal anti-SMN (BD
Transduction Labs 610646, 1:500), rabbit polyclonal anti-COPB1 (CUSAB,
College Park, MD, CSB-PA005783LA01HU, 1:500), mouse monoclonal
anti-Lamin A/C (Santa Cruz Biotechnology, sc-7292, 1:500), rabbit
polyclonal anti-NCDN (Proteintech 13187-1-AP, 1:500), mouse
monoclonal anti-tubulin (Sigma Aldrich, St Louis, MO, 1:500) and rabbit
polyclonal anti-Histone H3 (Proteintech 17168-1-AP, 1:300). Secondary
antibodies were goat anti-rabbit-IgG conjugated to Dylight 700 (Thermo
Scientific 35569, 1:15,000) or goat anti-mouse-IgG conjugated to Dylight
800 (Thermo Scientific SA5-10176, 1:15,000). Alternatively, goat anti-
mouse-IgG conjugated to IRDye 800CW (Li-Cor 925-32210, 1:25,000) and
goat anti-rabbit-IgG conjugated to IRDye 680RD (Li-Cor 925-68071,
1:25,000) were used. Goat anti-rat-IgG conjugated to Dylight 800 (Thermo
Scientific, SA5-10024) antibody was used to visualise the rat monoclonal
anti-RFP antibody at a concentration of 1:15,000. Donkey anti-goat-IgG
conjugated to IRDye 800CW (Licor, Lincoln, NE, 925-32214) was used at a
concentration of 1:25,000 to detect goat polyclonal anti-γCOP antibody.
Donkeyanti-rabbit-IgG conjugated to horseradish peroxidase (HRP) (Pierce,
Waltham,MA, 31460, 1:15,000) was used to identify endogenous NCDN in
Fig. 3D. Detection of antibodies conjugated to fluorophores was carried out
with an Odessey CLx using Image Studio (both Li-cor). Band quantification
was also performed by using Image Studio software. Detection of antibodies
conjugated to HRP was performed using ECL Western Blotting Substrate
(Pierce) and developed with Hyperfilm (Amersham), using a Kodak
X-OMAT 1000 developer, after 30-45 min exposure.
Immunoprecipitation of intact snRNPs
To immunoprecipitate intact snRNPS, whole-cell lysates were incubated
with anti-2,2,7-trimethylguanosine conjugated to agarose beads (Millipore
NA02A), with Sepharose 4B beads (Sigma-Aldrich) as a control. 40 ng of
pre-cleared lysate and unbound protein were separated by SDS-PAGE
alongside material precipitated with Sepharose control beads and TMG
antibody beads. Subsequent detection was carried out using rabbit anti-GFP
(1:2000, Abcam), rat mAb anti-RFP (1:500, Chromotek), mouse
monoclonal anti-SMN (1:500, BD Transduction Labs) and rabbit
polyclonal anti-SNRPN (1:800, Proteintech) antibodies.
Preparations and analysis of MS samples
SH-SY5Y cells constitutively expressing YFP, YFP–SNRPN or YFP–
SNRPB were lysed in co-immunoprecipitation buffer [10 mM Tris-HCl pH
7.5, 150 mM NaCl, 0.5 mM EDTA, 0.5% NP40, 1 cOmplete EDTA-free
protease inhibitor tablet (Roche) per 10 ml], followed by affinity
purification of the tagged proteins with GFP-Trap as above. 11 mg of
total protein per sample was used as input. 5 µl of the affinity isolated
material, alongside precleared lysate and unbound lysate was transferred to
nitrocellulose membrane (as above) and immunodetected using rabbit anti-
GFP antibody (Abcam) to confirm efficient immunoprecipitation. Samples
were then electrophoresed on a NuPAGE 4-12% Bis-Tris Acrylamide gel
(Novex, Waltham, MA, NP0321), Coomassie stained using SimplyBlue
SafeStain (Invitrogen, Paisley, UK), and gel chunks excised and analysed by
the Mass Spectrometry and Proteomics Facility at the University of
St Andrews.
The gel chunks were cut into 1 mm cubes. These were then subjected to
in-gel digestion, using a ProGest Investigator in-gel digestion robot
(Digilab, Hopkinton, MA) using standard protocols (Shevchenko et al.,
1996). Briefly, the gel cubes were destained by washing with MeCN and
subjected to reduction with DTT and alkylation with IAA before digestion
overnight with trypsin at 37°C. The peptides were extracted with 10%
formic acid, and the volume reduced to ∼20 µl by concentration in a
speedvac (Thermo Scientific).
The peptides were then injected onto an Acclaim PepMap 100 C18 trap
and an Acclaim PepMap RSLC C18 column (Thermo Scientific), using a
nanoLC Ultra 2D plus loading pump and nanoLC as-2 autosampler
(Eksigent). The peptides were eluted with a gradient of increasing
acetonitrile, containing 0.1% formic acid (2–20% acetonitrile in 90 min,
20–40% in a further 30 min, followed by 98% acetonitrile to clean the
column, before re-equilibration to 2% acetonitrile). The eluate was sprayed
directly into a TripleTOF 5600 electrospray tandem mass spectrometer
(Sciex, Foster City, CA) and analysed in Information Dependent
Acquisition (IDA) mode, performing 250 ms of MS followed by 100 ms
MS/MS analyses on the 20 most intense peaks seen by MS. The MS/MS
data files generated were analysed using the ProteinPilot Paragon search
algorithm v5.0.1 (Sciex) against the NCBInr database (Nov 2012) restricting
the search to Homo sapiens, with trypsin as the digestion enzyme and
selecting cysteine alkylation with iodoacetamide, ‘Gel based ID’ as a
‘Special factor’, ‘Biological modifications’ as the ‘ID Focus’ and a
‘Thorough’ ‘Search effort’.
ProteinPilot also performs a decoy database search to assess the false
discovery rate (FDR). Protein identifications were accepted if they were
identified by at least two peptides with the Detected Protein Threshold set at
0.05. The data was also analysed via the ‘Create mgf file’ script in PeakView
(Sciex) using the Mascot search algorithm (Matrix Science), against the
NCBInr database (Oct 2014) restricting the search to Homo sapiens
(284,317 sequences), trypsin as the cleavage enzyme and carbamidomethyl
as a fixed modification of cysteine residues and methionine oxidation as a
variable modification. The peptide mass tolerance was set to ±0.05 Da and
the MS/MS mass tolerance to ±0.1 Da. Scaffold viewer (version
Scaffold_4.5.1, Proteome Software) was used to validate the
identifications from Mascot. Peptide identifications were accepted if they
could be established at greater than 95.0% probability by the Peptide
Prophet algorithm (Keller et al., 2002). Protein identifications were accepted
if they could be established at greater than 99.0% probability and contained
at least two identified peptides. Protein probabilities were assigned by the
Protein Prophet algorithm (Nesvizhskii et al., 2003). Proteins that contained
similar peptides and could not be differentiated based on MS/MS analysis
alone were grouped to satisfy the principles of parsimony.
Identified proteins affinity purified alongside YFP–SNRPB or
YFP–SNRPN were discounted if they were additionally identified as
being affinity purified with YFP, or if they were present within the
Sepharose bead proteome (Trinkle-Mulcahy et al., 2008). The MS
proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE (Vizcaíno et al., 2016) partner repository with
the dataset identifier PXD008710.
RNAi assays
Reduction of protein expression using siRNAwas achieved by transfecting
the appropriate cell lines with siRNAs (Dharmacon, Lafayette, CO) using
Viromer Green [Lipocalyx GmbH, Halle (Saale), Germany] according to
the manufacturer’s instructions. Cells were lysed for immunoblotting assays
or fixed with paraformaldehyde for fluorescence microscopy at 48 h after
transfection. siRNA sequences used were SMN: 5′-CAGUGGAAA-
GUUGGGGACA-3′; SNRPB, a mixture of 5′-CCCACAAGGAAGAGG-
UACU-3′, GCAUAUUGAUUACAGGAUG-3′, 5′-CCGUAAGGCUGU-
ACAUAGU-3′ and 5′-CAAUGACAGUAGAGGGACC-3′; NCDN,
individually and a mixture of NCDN 18, 5′-GUUCAUUGGUGACGAG-
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AAA-3′, NCDN 19, 5′-AGACCUCAUCCUUGCGUAA-3′, NCDN 20, 5′-
AGGCCAAGAAUGACAGCGA-3′ and NCDN 21, 5′-GGCCAUU-
GAUAUCGCAGUU-3′; negative control (siControl) targeting luciferase,
5′-UAAGGCUAUGAAGAGAUAC-3′; positive control targeting Lamin
A/C, 5′-GGUGGUGACGAUCUGGGCU-3′; and SiGlo Cyclophillin B to
determine transfection efficiency, 5′-GGAAAGACUGUUCCAAAAA-3′.
Lysates were electrophoresed on an SDS-PAGE gel, transferred onto
nitrocellulose membrane, and immunodetected with antibodies to the above
proteins. Band signal intensity was determined with ImageStudio (Li-Cor),
and the values were normalised to tubulin, following correction for
background. Reduction of protein expression using shRNAwas achieved by
transfecting SH-SH5Y cell lines with pSUPER-GFP.Neo plasmids
(Oligoengine, Seattle, WA) expressing shRNA to SMN and Cyclophilin
B, which have been described previously (Clelland et al., 2012) using
Effectene (QIAGEN).
Fractionation
Cells were pelleted from the appropriate cell line, and incubated in Buffer
A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 1
cOmplete EDTA-free protease inhibitor tablet per 10 ml) for 5 min, before
being Dounce homogenised 25 times using the tight pestle to disrupt the
plasma membrane. This was then centrifuged at 300 g for 5 min to pellet
the nuclei. The supernatant was removed, recentrifuged at 300 g to further
remove nuclei, before the supernatant was centrifuged at 16,100 g for
30 min using a refrigerated 5415R Centrifuge (Eppendorf, Hamburg,
Germany). The nuclei were resuspended in buffer S1 (250 mM sucrose,
10 mM MgCl2), before this was layered over with buffer S3 (880 mM
Sucrose, 0.5 mMMgCl2). The nuclear pellet was then centrifuged at 2800
g for 10 min to wash and pellet the nuclei. The supernatant from the 16,100
g centrifugation was further centrifuged at 100,000 g using an Optima
Max-XP ultracentrifuge with a TLA-110 Rotor (Beckman-Coulter, Brea,
CA) for 60 min. The supernatant was removed and kept. The 16,100 and
100,000 g pellets were washed in Buffer A and centrifuged at 16,100 g for
30 min or 100,000 RCF for 1 h, respectively. Each pellet was then
resuspended in lysis buffer (see above). To confirm efficient separation of
cytoplasmic fractions from the nuclear fractions, mouse anti-tubulin
(Sigma-Aldrich, 1:500) and rabbit polyclonal anti-histone H3
(Proteintech, 1:300) antibodies were used.
Statistical analysis and generation of graphs
Data was processed using Microsoft Excel to produce ratios, proportions
and percentages. Bar charts and box-and-whisker plots were then
generated by using Prism 6 (GraphPad, La Jolla, CA) from the
processed data. Statistical analysis was also performed in Prism 6, with
multiple comparisons to determine statistical difference between specific
sets of data. Tukey post-tests were used to identify outliers in ANOVA
statistical analysis.
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(2011). Impaired minor tri-snRNP assembly generates differential splicing defects
of U12-type introns in lymphoblasts derived from a type I SMA patient. Hum. Mol.
Genet. 20, 641-648.
Bowerman, M., Shafey, D. and Kothary, R. (2007). Smn depletion alters profilin II
expression and leads to upregulation of the RhoA/ROCK pathway and defects in
neuronal integrity. J. Mol. Neurosci. 32, 120-131.
Boyd, P. J., Tu,W.-Y., Shorrock, H. K., Groen, E. J. N., Carter, R. N., Powis, R. A.,
Thomson, S. R., Thomson, D., Graham, L. C., Motyl, A. A. L. et al. (2017).
Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a
zebrafish model of spinal muscular atrophy. PLoS Genet. 13, e1006744.
Bucci, C., Parton, R. G., Mather, I. H., Stunnenberg, H., Simons, K., Hoflack, B.
and Zerial, M. (1992). The small GTPase rab5 functions as a regulatory factor in
the early endocytic pathway. Cell 70, 715-728.
Campbell, L., Potter, A., Ignatius, J., Dubowitz, V. and Davies, K. (1997).
Genomic variation and gene conversion in spinal muscular atrophy: implications
for disease process and clinical phenotype. Am. J. Hum. Genet. 61, 40-50.
Chen, Y., Xu, Y., Li, G., Li, N., Yu, T., Yao, R.-E., Wang, X., Shen, Y. andWang, J.
(2017). Exome sequencing identifies de novo DYNC1H1 mutations associated
with distal spinal muscular atrophy and malformations of cortical development.
J. Child Neurol. 32, 379-386.
Clelland, A. K., Kinnear, N. P., Oram, L., Burza, J. and Sleeman, J. E. (2009). The
SMN protein is a key regulator of nuclear architecture in differentiating
neuroblastoma cells. Traffic 10, 1585-1598.
Clelland, A. K., Bales, A. B. E. and Sleeman, J. E. (2012). Changes in intranuclear
mobility of mature snRNPs provide a mechanism for splicing defects in spinal
muscular atrophy. J. Cell Sci. 125, 2626-2637.
Corey, D. R. (2017). Nusinersen, an antisense oligonucleotide drug for spinal
muscular atrophy. Nat. Neurosci. 20, 497-499.
Custer, S. K., Todd, A. G., Singh, N. N. andAndrophy, E. J. (2013). Dilysinemotifs
in exon 2b of SMN protein mediate binding to the COPI vesicle protein alpha-COP
and neurite outgrowth in a cell culturemodel of spinal muscular atrophy.Hum.Mol.
Genet. 22, 4043-4052.
Custer, S. K., Gilson, T. D., Li, H., Todd, A. G., Astroski, J. W., Lin, H., Liu, Y. and
Androphy, E. J. (2016). Altered mRNA splicing in SMN-depleted motor neuron-
like cells. PLoS ONE 11, e0163954.
Dateki, M., Horii, T., Kasuya, Y., Mochizuki, R., Nagao, Y., Ishida, J., Sugiyama,
F., Tanimoto, K., Yagami, K., Imai, H. et al. (2005). Neurochondrin negatively
regulates CaMKII phosphorylation, and nervous system-specific gene disruption
results in epileptic seizure. J. Biol. Chem. 280, 20503-20508.
De Duve, C. (1971). Tissue fractionation. Past and present. J. Cell Biol. 50, 20d-55d.
Dimitriadi, M., Derdowski, A., Kalloo, G., Maginnis, M. S., O’Hern, P., Bliska, B.,
Sorkac, A., Nguyen, K. C. Q., Cook, S. J., Poulogiannis, G. et al. (2016).
15
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs211482. doi:10.1242/jcs.211482
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
Decreased function of survival motor neuron protein impairs endocytic pathways.
Proc. Natl. Acad. Sci. USA 113, E4377-E4386.
Ding, D., Chen, Z., Li, K., Long, Z., Ye, W., Tang, Z., Xia, K., Qiu, R., Tang, B. and
Jiang, H. (2016). Identification of a de novo DYNC1H1 mutation via WES
according to published guidelines. Sci. Rep. 6, 20423.
Doktor, T. K., Hua, Y., Andersen, H. S., Brøner, S., Liu, Y. H., Wieckowska, A.,
Dembic, M., Bruun, G. H., Krainer, A. R. and Andresen, B. S. (2017). RNA-
sequencing of a mouse-model of spinal muscular atrophy reveals tissue-wide
changes in splicing of U12-dependent introns. Nucleic Acids Res. 45, 395-416.
Doyle, M. and Kiebler, M. A. (2011). Mechanisms of dendritic mRNA transport and
its role in synaptic tagging. EMBO J. 30, 3540-3552.
Fallini, C., Zhang, H., Su, Y., Silani, V., Singer, R. H., Rossoll, W. and Bassell,
G. J. (2011). The survival of motor neuron (SMN) protein interacts with themRNA-
binding protein HuD and regulates localization of poly(A) mRNA in primary motor
neuron axons. J. Neurosci. 31, 3914-3925.
Fallini, C., Rouanet, J. P., Donlin-Asp, P. G., Guo, P., Zhang, H., Singer, R. H.,
Rossoll, W. and Bassell, G. J. (2014). Dynamics of survival of motor neuron
(SMN) protein interaction with the mRNA-binding protein IMP1 facilitates its
trafficking into motor neuron axons. Dev. Neurobiol. 74, 319-332.
Fallini, C., Donlin-Asp, P. G., Rouanet, J. P., Bassell, G. J. and Rossoll, W.
(2016). Deficiency of the survival of motor neuron protein impairs mRNA
localization and local translation in the growth cone of motor neurons.
J. Neurosci. 36, 3811-3820.
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C.,
Yamashita, M., Rigo, F., Hung, G., Schneider, E. et al. (2016). Treatment of
infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label,
dose-escalation study. Lancet 388, 3017-3026.
Fischer, U., Liu, Q. and Dreyfuss, G. (1997). The SMN-SIP1 complex has an
essential role in spliceosomal snRNP biogenesis. Cell 90, 1023-1029.
Fischer, U., Englbrecht, C. andChari, A. (2011). Biogenesis of spliceosomal small
nuclear ribonucleoproteins. Wiley Interdiscip Rev. RNA 2, 718-731.
Francke, F., Ward, R. J., Jenkins, L., Kellett, E., Richter, D., Milligan, G. and
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